In previous work, we proposed 
The American trypanosomiasis described in Minas Gerais, Brazil, by Carlos Chagas (1909) and caused by Trypanosoma cruzi, is endemic in Latin America countries and particularly affects the impoverished populations. There is great regional variability in the clinical symptoms due to Chagas disease, ranging from asymptomatic cases to severe cardiac and digestive forms (Coura 2007) . Most patients are diagnosed late in the chronic phase, decades after the initial infection with the parasite. In the first weeks after T. cruzi infection, trypomastigotes are detected in blood samples by microscopic examination, but parasitemia is rapidly controlled and becomes extremely low (Fig. 1) . It is believed that there is no spontaneous cure and that the infection persists for the lifetime of humans and laboratory animals as either latent or pathogenic parasitism.
The control of parasitemia in the chronic phase is mainly mediated by anti-trypomastigote stage-specific antibodies that neutralize the parasite infectivity and which may be transferred by serum transfusion to naïve mice (Krettli & Brener 1976 , Krettli 1978 . It is extremely difficult to demonstrate circulating parasites during the chronic disease, as their detection requires indirect parasitological tests: (i) xenodiagnosis, with laboratory raised triatomines or (ii) blood culture in complex LIT medium, as described by Camargo (1964) . However both tests have low sensitivity. Repeated hemocultures may uncover parasites in less then half of the chronic cases, even in untreated patients . Outbreaks of high parasitemia are frequent in immunosuppressed patients with a chronic T. cruzi infection, especially in HIV co-infections and in individuals using immunosupressive drugs. Reactivation of Chagas disease symptoms also may occur in human immunodeficiency virus-infected patients and lead to severe heart disease and late positive direct microscopic examination of the blood (Sartori et al. 1998) .
Chagas disease causes a significant burden and economic loss in Latin America and it is estimated that 8-10 million individuals are in the chronic phase in Latin America in spite of control measures taken to eliminate natural transmission (through eradication of Triatoma infestans -the most important vector in natural transmission) (Dias 2007) . Disease transmission still occurs by blood transfusion, congenital and organ transplantation, and through metacyclic forms orally (Shikanai-Yasuda et al. 1991) ; this mode of transmission responsible for frequent outbreaks of the disease in recent years, including in the Amazon Region (Coura 2007) , causes acute infections with high morbidity. Recent migratory trends have spread the disease to non-endemic countries (Moncayo & Ortiz Yanine 2006) .
Those in charge of the control and management of the chronic disease face important problems regarding drug treatment and protocols to determine cures. Diagnosis of the chronic disease is mostly based on detection of specific antibodies by conventional serology (CS) due to the difficulty of finding parasites. The CS tests available for diagnosis of Chagas disease detect specific antibodies measured against parasite antigens, usually extracts from epimastigote stages (in axenic medium) (Camargo 1964) . The CS tests used in clinical laboratories vary within countries according to available reagents and protocols; the most widely used are listed as follows: (i) the complement fixation reaction (CFR), as first described by Guerreiro and Machado (1913) and later modified by Muniz and Freitas (1944a, b) ; (ii) the direct agglutination of killed parasites; (iii) the indirect agglutination of red blood cells pre-sensitized with parasite antigens and (iv) the indirect immunofluorescence tests (IIF) with fixed cultured parasites. The standardization of these various tests and protocols was made possible by a multicentric study involving several laboratories in different countries (Camargo et al. 1986 ) and other studies with commercially available tests (Leiby et al. 2000 , Gadelha et al. 2003 .
The management of treated patients in the chronic phase is complex since the detection of parasites is difficult before treatment and becomes even more difficult after treatment . In many treated patients, the clinician relies on positive CS tests for diagnosis and for the follow-up after treatment. Although CS reverts to negative in most patients (80%) treated in the acute phase of infection, such reversion seems unusual among the treated groups with chronic disease. In various clinical trials with compounds shown to be active against T. cruzi in the acute phase, reversion of CS during the chronic infection is less then 10%.
In groups of Chagas patients classified by JR Cançado as untreated, treated but not cured, and cured after drug treatment (serology and parasitological tests repeatedly negative), various classes of circulating anti-parasite antibodies were tested by CS, in parallel with tests for functional antibodies using live trypomastigotes . For the latter, trypomastigotes freshly isolated from tissue culture or from gamma-irradiated mice were used in a complement-mediated antibody dependent lysis (CoML) test (Krettli et al. 1979 ) with the hope of establishing better protocols for discriminating individuals who harbor a T. cruzi infection after drug treatment from those who eliminated the infection. Evidences that antibodies directed to epitopes anchored on the surface of live trypomastigotes are reliable indicators of ongoing infection are systematically reviewed. In addition, other tests which detect the functional antibodies by ELISA with recombinant antigens are examined in the hope to find a better and more practical test to replace the CoML test.
MATERIALS AND METHODS
All the Chagas patients analyzed in this review had been treated (Nifurtimox and/or Benznidazole, one or more times) and managed by JR Cançado (Federal University of Minas Gerais, Belo Horizonte, MG). Our long term collaboration began in 1979, when the CoML test was included in the follow-up of his patients. Several individuals previously treated during the chronic phase had already been classified as cured or as a therapeutic failure by JR Cançado, based on the CS tests, which were repeatedly negative or positive, respectively; some were also tested by hemocultures.
All human sera were received coded at our laboratory and included control samples from untreated and from non-infected subjects. Human serum samples from blood donors or laboratory staff were also included and the protocols were described previously in our work. The steps of the CoML test are summarized in Fig. 2 . The CoML tests were performed using fresh suspensions of T. cruzi Y strain originally isolated from a patient (Silva & Nussezweig 1953) , maintained in mice by serial blood passages and obtained from immunossupressed animals or from tissue cultures (Krettli et al. 1979 . The same serum samples were used in the CoML tests and in the CS and the latter were performed by Rosa Maria Brigito Nunes, at the Laboratory of Immunology, Instituto de Pesquisas René Rachou-Fiocruz, following standard protocols for IIF and CFR used in the routine tests for diagnosis of the human disease.
RESULTS
During T. cruzi chronic infections, the vertebrate host produces antibodies at high levels against the parasite, used as markers of ongoing infections in the diagnostic tests of CS. Some IgG antibodies are functional and directed to proteins at the surface of living trypomastigotes being detected by CoML, IIF, direct agglutination and neutralization of parasite infectivity. The antibodies detected by the CoML are not induced in mice by immunization with T. cruzi extracts, with some purified glicoproteins (Snary & Hudson 1979) , or by their inoculation with live non-infectious trypanosomatides (Table I) . Specific antibodies from T. cruzi chronic infections, but not antibodies from the immunized but non-infected mice, affect the infectivity of Y strain trypomastigotes upon incubation at various temperatures, causing lower para- sitemias than parasites incubated with control sera from normal animals (Fig. 3A) . Trypomastigotes from most T. cruzi strains induce protective antibodies in mice at the chronic phase, but not all strains are equally affected in the direct agglutination or in the neutralization test (CL or Gilmar strains are not) (Krettli & Brener 1976) .
The CoML test is specific and highly sensitive, allowing detection of anti-T. cruzi antibodies in sera from all humans and experimental animals in chronic phases of infections. The lysis of blood trypomastigote for practical reasons is performed with the Y strain parasites, easier to maintain and to isolate from the infected mice. The source of complement used in the CoML test is fresh human serum from healthy donors, but any other fresh serum may be used (except sera from chicken or other avian animals known to induce direct lysis independent of antibodies). The mechanism of trypomastigote lysis in the CoML test is through the alternative pathway of complement activation, as summarized in Fig.  3 , further discussed below and as previously reviewed (Krautz et al. 2000) . The susceptibility of T. cruzi trypomastigotes to complement lysis needs to be tested each time after their isolation (from immunosuppressed mice or from cell cultures); only suspensions totally refractory to direct complement lysis are useful for the CoML test. The specificity of the CoML test is high, as none of the 50 controls (blood donors and laboratory staff) was positive (Table II) . In addition, in a total of 250 tests with sera from 10 different non-infected subjects, borderline lysis (~20%) activity was observed . All the patients with a chronic untreated infection were positive in the CoML test and all the treated individuals that were negative in the CS test were also negative in the CoML test (Table II) .
The levels of anti-trypomastigote antibodies measured in the CoML tests in 101 untreated patients submitted to repeated hemocultures were quantified . Among the untreated patients hemocultures were positive in 47%; in the treated patients considered as therapeutic failures (CS and CoML-positive) 24% were positive by hemoculture. The analysis of sera from individuals with positive hemocultures showed in general a slightly higher activity (40-100% lysis) than sera from untreated patients with negative hemocultures (20-90% lysis). The data suggest that these antibodies are maintained by trypomastigote-specific antigens during the chronic human infections, soon after parasite elimination their level decrease to become then negative. The idea is further sup-ported by results of the CoML tests in treated and untreated patients (Table II) . The data of CS and CoML allow a clear separation of the treated groups: (i) patients considered not cured, positive by CS and CoML test; (ii) patients with repeated negative hemocultures and negative tests for lytic antibodies but positive by CS were considered cured, the group "dissociated" since the sera is positive by CS test and negative by CoML and (iii) cured patients, negative by CS, CoML and repeated hemocultures.
The results of the serologic and parasitological tests in 12 treated patients considered as therapeutic failures (group i) are summarized in Table III . In these patients, the CS test was persistently clearly positive (IIF and CFR) 6-12 years after the initial specific treatment. However, the number of positive sera in the CoML test varied from persistently positive (> 43% positive sera) in six patients to oscillating rarely positive (< 30% positive sera) in others. Their classification as cured individuals or therapeutic failures remains questionable. It is likely that most of them have eliminated the infection. There are several possible explanations for persistent serology in the absence of an ongoing infection, as will be discussed further.
In a follow up study of 15 years ), the majority of treated patients with negative CoML tests remained positive by CS test for many years; some never reverted the CS (patient ACS, treated at the chronic phase); a few patients reverted the CS to negative years later, as illustrated in the case of JFS, considered cured (Table IV) . The evolution of the tests showed that the four serum samples collected during the first seven months after specific treatment of JFS were positive and that CoML was the first test to revert to negative nine months later (except for 1 serum among 20 tested that had low lytic activity -36% lysis -likely to be a false positive test). The CS remained positive until 26 months after treatment and finally became negative 53 months later. In summary, JFS could be considered cured in the first year of treatment. Among the group with acute infections, 80% were considered cured, but we had the chance to test the CoML in only two cases (MVC, JBS), and both reverted to negative a few months after treatment. The CS also reverted in MVC but remained positive in JBS many years after treatment.
ELISA with purified trypomastigote antigens may replace the CoML test -The target epitope for the lytic antibodies has been identified in the trypomastigote surface (Martins et al. 1985) through western blot analysis with hyperimmune sera from T. cruzi chronic infections. A high molecular weight protein (160 kDa -gp160) precipitated by sera from mice and humans with ongoing chronic infections was not bound by normal control sera or sera from treated and cured individuals. A total correlation was found between serum lytic activity and the recognition of gp160. Later gp160 was purified and characterized by Norris et al. (1991) as a protein that binds the complement C3 component and it has genetic similarities to the decay accelerating factor human complement regulatory protein (CRP) (Fig. 4) . These data confirm previous results showing that the activity of specific lytic antibodies can be induced by immunoglobulin fragments (FAB) that mediate complement lysis of trypomastigotes (Kipnis et al. 1985) .
The purified 160 kDa protein was successfully used in western blot analysis, being recognized by all sera from treated patients considered not cured (positive CoML and CS tests), but not by sera with negative CoML or sera negative in western blot tests (Norris et al. 1994 ). Other glycoproteins (GP57/51) used in immunoassays (ELISA) resulted in negative tests in 70% of patients from the group presumably cured. The calcium binding protein of low molecular weight (Tc24) also had a good correlation with the CoML test (86%) (Krautz et al. 1995) . The heat-shock proteins, especially HP70, were proven to be reliable antigens to assess cure after chemotherapy and replaced the CoML test in the followup of treated patients (Krautz et al. 1998 ). These antigens were successfully used in ELISA tests and showed a high correlation with the results of the CoML test when the same sera (from patients treated and cured) were used in parallel (Table V) . The protocols for antigen purification and the rationale for selection of the various proteins listed are described in the cited references and are not a subject of this review.
DISCUSSION
There is only one study in the literature, as far as I know, where a patient was monitored with parasitological and serologic tests, including the CoML, immediately after infection and subsequently to the specific treatment (Israelski et al. 1985) . In sequential serum samples of an individual accidentally infected with T. cruzi at a research laboratory, the authors studied the evolution of the antibody response by serology and western blot analysis before and after treatment. The CoML test was the first to detect specific antibodies, two weeks before demonstration of parasitemia and before antibodies could be detected by CS (using ELISA and IIF tests). At day 35 after infection, the ELISA and IFA tests became positive for specific antibodies to T. cruzi; the CoML test detected 89% lysis activity. Serum samples collected at different periods of time during this human T. cruzi infection were valuable for evaluating the success of the specific therapy and to establish a cure; all tests became negative after 300 days. Several other purified antigens from T. cruzi are commercially available for the diagnosis of Chagas disease using ELISA, but only one has been evaluated in controlled clinical trials using treatedpresumably-cured patients (Silva et al. 2002 , Gadelha et al. 2003 , Lorena et al. 2008 . The data are summarized in Table V and discussed below. We remain in need of more practical serological tests and further well-controlled double-blind trials.
In our studies, there were only two cases of acute infections treated and followed up, and both were cured. The CoML was the first test to become negative (one or two years after treatment). In the other cured patients (Table II) , the serological tests were already negative (CS) when we first started to evaluate criteria for defin- ing cure using CoML, and they all remained negative . In patients treated during the chronic phase considered presumably cured (negative CoML and parasitological tests), antibodies not recognized by trypomastigote antigens are responsible for the positive CS. Anti-laminin antibodies and other antibodies to epitopes with glucose residues are generated by antigens present in T. cruzi and in other pathogens (Gazzinelli et al. 1987 (Gazzinelli et al. , 1988 . Further studies of serum reactivity in ELISA with purified parasite surface molecules may help to clarify this important practical issue: in the presumably cured group and in other patients so far considered as therapeutic failures, how long do we have to wait before considering them free of the infection? Several possibilities may explain the remaining CS after elimination of the parasites, as follows.
Why does CS remain positive after drug treatment and cure of the patients? -Chagas disease is believed
to be an autoimmune disease. Cross reactions have been described in patients and in experimental animals by many groups. The permanence of an immune response after the parasites are eliminated is expected, generated by self-antigens. Heart proteins may exhibit cross-reactivity with the parasite surface, a phenomenon known as molecular mimicry, and the antibodies are maintained by host antigens (Garcia et al. 2005) . As in other infections, once the parasites disappear by drug treatment, antigens remains in cured animals in phagocytic cells, dendritic cells, and macrophages, long after the infection was eliminated by treatment and cure in mice. This may well happen in human cured infections. In addition, carbohydrate determinants present in microorganisms of intestinal and pulmonary microflora (like Galactosyl-α-Galactose) could stimulate lymphocytes previously primed by the T. cruzi epitopes, thereby maintaining the positive serology in patients who have cleared the infection. In the human acute phase of Chagas disease, high levels of anti-laminin antibodies circulate and induce direct lysis of the trypomastigotes, and this is considered to be a mechanism of natural resistance to the parasite (Gazzinelli et al. 1988) . A high proportion of antibodies detected by CS tests are directed against carbohydrate residues. Indeed, sera negative in CoML tests also became negative in the CS test following immunoadsorption with melibiose (Gazzinelli et al. 1993) .
Which tests could replace the CoML lytic antibody assay? -Flow cytometry has been suggested as a method to replace the CoML test (Martins-Filho et al. 1995) . The authors tested human sera from patients in groups previously categorized as untreated, treated-cured and treatment failure . Sera were used to coat live trypomastigotes (1:256 dilution), allowing quantification of antibodies in the chronic phase of Chagas disease by flow cytometry. All non-chagasic controls were negative, all the untreated controls were positive and all the cured patients (negative CS and negative CoML) were negative. Thus, it distinguished cured from non-cured. However, among some treated individuals with positive CS but negative CoML (presumably cured), the flow cytometry test and CoML did not correlate. A wide degree of reactivity was observed in sera negative by CoML. This result places the flow cytometry assay in the same category as the CS tests. Since the amount of serum defined as positive in flow cytometry (1:256) is significantly lower than that required for the lytic antibodies (1:8 final dilution), the former is likely to detect other antibodies not directed against the gp160 CRP epitope. In addition, flow cytometry has the same limitation as the CoML test in that they both require live parasites. Whether using trypomastigotes and epimastigotes, as recently shown by MartinsFilho et al. (2002) , flow cytometry does not seem to re -TABLE IV One patient with a chronic Trypanosoma cruzi infection, considered to be a therapeutic success, reverted the complementmediated lysis (CoML) test in the first year after specific treatment, but remained positive by conventional serology up to six years, at which point these tests also became negative place the CoML test when defining success after drug treatment in patients with a chronic T. cruzi infection. Commercially available ELISA have been evaluated for accuracy in the diagnosis of Chagas disease. Most of the commercial serologic tests employ epimastigote antigens and show a high number of inconclusive and false-positive results, with high economic and social costs (Umezawa et al. 2003) . Some ELISA kits show up to 100% sensitivity but variable specificity (82-100% when leishmaniasis cases were included); others using recombinant antigens or synthetic peptides are more specific than crude extracts from T. cruzi epimastigote forms, with sensitivity ranging from 75-100% (Caballero et al. 2007) . A western blot assay with excreted-secreted antigens from live T. cruzi trypomastigotes from tissue cultures (highly sensitive and specific) was used as a reference test to confirm parasite infections. Other commercially available ELISA kits use recombinant T. cruzi antigens with high sensitivity and specificity, but are not sensitive enough for serological screening of blood banks as they result in a large number of inconclusive tests and significant discharge of human blood samples.
In one study, a commercially available recombinant ELISA kit produced in Biomanguinhos-Fiocruz, a cytoplasmic repetitive antigen and a flagellar repetitive antigen (Krieger et al. 1992 ) was used to test sera from patients treated with anti-T. cruzi drugs. These are the same patients of JR Cançado that we previously classified (Table II) based on CoML, CS and hemoculture tests. In treated patients considered cured, all tests were negative; in the dissociated patients (DP), CoML was negative and CS persistently positive. The ELISA data (Silva et al. 2002) were also negative in all sera from the 10 cured patients and in all sera from non-chagasic subjects. In addition, all the untreated and the treated noncured patients were positive. However, among the six sera from the DP group, four sera were negative, one was borderline and one was positive by ELISA. Thus there was some correlation between the lytic antibody test and ELISA with recombinant T. cruzi antigens (Table V) . Since this is the only available kit tested so far, more sera should be tested in other groups of well-characterized patients so that recombinant ELISA tests are included in protocols to manage treated patients. The other tests showing 100% correlation (Table V) are with in-house antigens not commercially available and most were also performed with a limited number of sera.
Crude extracts of T. cruzi (excreted from live trypomastigotes) showed 100% correlation with CoML when tested by immunoblot (Martins et al. 1985 , Norris et al. 1991 or in ELISA (Krautz et al. 1994) . The CRP anchored in the surface of living trypomastigotes is the target epitope for the lytic antibodies and is responsible for the control of parasite resistance to complement lysis in the absence of specific antibodies (Fig. 4) . As expected, CRP showed the best correlation (Norris et al. 1991 (Norris et al. , 1994 , including when used as a recombinant protein (Meira et al. 2004) , but a rather limited number of patient sera have been sampled. If the data is confirmed with other DPs it will be the ideal antigen to be selected. Hopefully a recombinant ELISA kit will soon be available to replace the CoML test and flow cytometry (Martins-Filho et al. 2002) , since both require live infectious trypomastigotes and are not practical for patient management.
There is still controversy concerning the benefits and risks of benznidazole treatment, which is the only Viotti (2009) , a problem since the affected patients usually were infected decades ago. Treatment prevents the development of severe chronic cardiomyopathy in mice, despite the lack of complete parasite eradication. Treatment also reduces the levels of antibodies against beta-adrenergic and muscarinic cardiac receptors (Garcia et al. 2005) .
The results reinforce the importance of T. cruzi elimination as a way to decrease or prevent development of severe Chagasic cardiomyopathy. There is also an urgent need for further evaluation of treated patients using protocols other than traditional serology to detect elimination of the infection upon drug treatment. There is no solid evidence of spontaneous cure of the T. cruzi infection but all chronic patients live with extremely low parasitemias, yet some develop morbidity that tends to increase with the patient's age (Rassi-Jr et al. 2006) , some with hurt failure or other complications and death. The demonstration of parasites strains with natural cross-resistance to anti-T. cruzi available drugs (Filardi & Brener 1987) creates an additional problem when treating patients. The identification of genes differentially activated in the drug resistant strains was recently confirmed by modern technologies of genomic, proteomic, microarrays, differential display and gene expression (Andrade et al. 2008) .
The use of negative CS to differentiate cured from non-cured patients seems to be a confounding variable since the specific anti-T. cruzi immune response can be maintained after parasite elimination. In many other parasitic diseases, including malaria, CS tests are not included in protocols for control of drug efficiency. When symptoms are evident parasites can easily be detected. Better methods of patient evaluation after treatment will help in the search for new drugs in clinical trials, and stop the unnecessary burden on the affected population in endemic areas.
That treatment has to be undertaken seems to be a consensus among clinicians, and the remaining questions are of several orders. To face new challenges and use new protocols with patients is urgent, especially considering that asymptomatic infection in apparently healthy individuals will progress to a symptomatic disease in half of the cases. Many questions remain, in special, why 6-9% of patients treated in the chronic phase revert to CS negative? How long the other treated patients have to wait before conclusion of a therapeutic failure versus a cure? If there is a drug-resistant parasite, how many times does one need to be treated to be cure? Which laboratory tests revert after treatment? What is the meaning of the persistent antibodies after the parasite has been eliminated? Several other items have been listed by Coura (2007) as priorities in the search for solutions for this 100-year-old disease. The use of selected antigens or peptides from the parasite in ELISAs may be useful for evaluating cure after treatment. Now that the parasite's genome is sequenced, other approaches may lead to the discovery of new drugs against T. cruzi, as well as to new tests for the detection of cure after treatment of chronic infections, the PCR seems to be the best tool to control cure after treatment, and the technique is well revised by Constança Brito in this same journal issue. Let us hope that the discussions during the celebrations of the centenary of Carlos Chagas' genial discoveries will bring new light and new approaches to find solutions for urgent problems hampering disease control.
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